Healthcare Technology · near ·
Pharma M&A is outrunning its AI due diligence bottleneck
Pharmaceutical companies are increasingly seeking AI partnerships for deep, governed integration into R&D and commercial workflows. Concurrently, PE firms are actively acquiring specific AI capabilities for clinical trial data management. This indicates that AI capability audits are becoming a critical but underdeveloped component of pharma M&A due diligence.
Part of the Healthcare & Life Sciences Opportunity Outlook, Korim's monthly analysis of emerging opportunities in this sector.